Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II
Status:
Active, not recruiting
Trial end date:
2022-03-23
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to assess the effects of ticagrelor plus aspirin
versus clopidogrel plus aspirin on reducing the 3-month risk of any stroke (both ischemic and
hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in CYP2Y19 LOF
alleles carriers with TIA or minor stroke.
Phase:
Phase 3
Details
Lead Sponsor:
Beijing Tiantan Hospital Peking University Third Hospital
Collaborators:
Beijing Tiantan Hospital Ministry of Science and Technology of the People´s Republic of China